MV Chandrakanth: Ivonescimab’s PFS Win, OS Miss – FDA Says No
MV Chandrakanth/X

MV Chandrakanth: Ivonescimab’s PFS Win, OS Miss – FDA Says No

MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X:

“Ivonescimab:PFS win, OS miss – FDA says no!

HARMONi Phase III, FDA Complete Response Letter (CRL).

  • Population: EGFR-mutated advanced nonsquamous NSCLC after 3rd-generation EGFR TKI.
  • Design: Ivonescimab + platinum chemotherapy vs placebo + chemotherapy.
  • PFS: Statistically significant improvement.
  • OS: Not statistically significant Post-hoc HR 0.76 – favorable trend, no proven OS benefit.
  • FDA verdict: Benefit-risk evidence insufficient for approval as submitted.
  • Regulatory status: In the USA Not FDA-approved, in China-Initially approved May 2024.

What’s next? HARMONi-3, HARMONi-7 and broader clinical development continue.

Take-Home: PFS success ≠ OS success ≠ FDA approval.

Reference: Summit Therapeutics, November 15, 2026, HARMONi Phase III, FDA CRL announcement.”

You can also read: